CompletedPhase 4

Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC)

China131 participantsStarted 2010-12

Plain-language summary

The purpose of this study is to determine the safety and efficacy of PDT at 30% verteporfin dose in the treatment of CSC.

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients with CSC * patients signed the ICF * patients with course of CSC less than 6 months * patients did not undertake any treatment for CSC Exclusion Criteria: * patients with porphyria * patients allergic to verteporfin * pregnant or nursing women * poor patients compliance * sever liver dysfunction * dioptric media opacities which make it difficult to exam fundus

What they're measuring

Change from baseline in BCVA

Timeframe: 1 week,2 weeks,3 weeks,1 month,3months, 6 months, 1 year

Trial details

NCT IDNCT01574430

SponsorPeking University People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-12

View on ClinicalTrials.gov More Central Serous Chorioretinopathy trials